Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant advances » significant advantages (Expand Search), significantly advanced (Expand Search), significant advancements (Expand Search)
advances decrease » advanced disease (Expand Search), advanced defense (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant advances » significant advantages (Expand Search), significantly advanced (Expand Search), significant advancements (Expand Search)
advances decrease » advanced disease (Expand Search), advanced defense (Expand Search)
-
2121
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2122
-
2123
-
2124
-
2125
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2126
-
2127
-
2128
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2129
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2130
-
2131
-
2132
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2133
-
2134
-
2135
-
2136
-
2137
-
2138
-
2139
-
2140